H-ICC is characterized by hyperenhancement occupying ≥ 50% of the tumor area on dynamic CT, high AVD, and elevated VEGFA expression. These findings support a distinct clinicopathological subset identifiable by LAP enhancement and VEGF immunostaining.
Tsuzaki et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: